This content is in French.
After leukemia, a lifelong follow-up!
28 février 2025
#Leukemia #ALL #AML #LongTermFollowUp #Oncology #Cancer
Thanks to advances in pediatric oncology, the vast majority of children with acute leukemia are now cured. More than 90% of patients with acute lymphoblastic leukemia (ALL) and about 60 to 70% of children with acute myeloid leukemia (AML) survive thanks to progress in chemotherapy, immunotherapy, and stem cell transplantation.
However, these aggressive treatments lead to late side effects that can impact survivors’ quality of life. Around 20% of former ALL patients and the majority of AML survivors develop a chronic illness within 20 to 25 years of diagnosis. These complications often affect the heart, metabolism, bones, or nervous system, increasing the risk of premature mortality.
Thanks to advances in pediatric oncology, the vast majority of children with acute leukemia are now cured. More than 90% of patients with acute lymphoblastic leukemia (ALL) and about 60 to 70% of children with acute myeloid leukemia (AML) survive thanks to progress in chemotherapy, immunotherapy, and stem cell transplantation.
However, these aggressive treatments lead to late side effects that can impact survivors’ quality of life. Around 20% of former ALL patients and the majority of AML survivors develop a chronic illness within 20 to 25 years of diagnosis. These complications often affect the heart, metabolism, bones, or nervous system, increasing the risk of premature mortality.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Roganovic, J., et al. (2024). Late adverse effects after treatment for childhood acute leukemia. Acta Medica Academica, 53(1), 59
View the source
